Ipamorelin and CJC-1295: Growth Hormone Secretagogue Research Overview

Disclaimer: This article is written for research and educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before making any decisions about your health or supplementation.

What Are Growth Hormone Secretagogues?

Growth hormone secretagogues (GHS) are a class of compounds that stimulate the release of growth hormone (GH) from the anterior pituitary gland. Unlike exogenous growth hormone — which introduces synthetic GH directly into the bloodstream — secretagogues act upstream, amplifying the body's own pulsatile GH release mechanisms.

This distinction is clinically meaningful. Exogenous GH administration suppresses endogenous production through negative feedback on the hypothalamic-pituitary axis. Secretagogues, by contrast, work within the body's existing regulatory framework, preserving the natural pulsatile pattern of GH secretion that is associated with physiological signalling.

Two compounds in particular have attracted sustained research attention: ipamorelin, a selective GH secretagogue receptor agonist, and CJC-1295, a modified growth hormone-releasing hormone (GHRH) analogue. Their complementary mechanisms have made them a common focus of combinatorial peptide research.

Ipamorelin: Selective Ghrelin Receptor Agonism

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a pentapeptide that acts as an agonist at the GHS receptor type 1a (GHS-R1a), the same receptor activated by ghrelin. It was first characterised in research by Raun et al. (1998) and distinguished itself from earlier GH secretagogues by its high selectivity for GH release over other pituitary hormones.

Earlier compounds in the GHS class — including GHRP-2 and GHRP-6 — also stimulated GH release but were associated with off-target effects, particularly significant elevations in cortisol and prolactin at research concentrations. These effects are undesirable in research contexts seeking to isolate GH-axis responses.

Ipamorelin's defining characteristic is its exceptional selectivity. At doses that produce substantial GH release, it does not significantly stimulate cortisol, prolactin, or ACTH secretion. The original characterisation study in rats demonstrated that ipamorelin produced GH pulses of magnitude comparable to GHRP-6 while generating cortisol and prolactin responses no greater than saline controls: Raun et al., 1998 — Ipamorelin, the first selective growth hormone secretagogue.

This selectivity profile makes ipamorelin a useful research tool for studies specifically examining GH-axis function and downstream IGF-1 responses without the confounding influence of cortisol co-elevation.

CJC-1295: GHRH Analogue with Extended Half-Life

CJC-1295 operates through a different mechanism. Where ipamorelin mimics ghrelin signalling, CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) — the hypothalamic peptide that drives GH secretion from the pituitary.

Native GHRH has a very short plasma half-life of approximately 7 minutes, limiting its utility in research protocols. CJC-1295 addresses this through chemical modifications that dramatically extend its circulating half-life. The compound's specific form — CJC-1295 without drug affinity complex (DAC) — has a half-life estimated at approximately 30 minutes, while the DAC-conjugated version can extend activity to several days through albumin binding.

The phase 1 clinical trial by Alba et al. (2006) in healthy adults demonstrated that a single subcutaneous dose of CJC-1295 produced dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold, with elevated IGF-1 levels persisting for up to 6 days post-injection: Alba et al., 2006 — Dose-dependent pharmacokinetics and pharmacodynamics of CJC-1295.

The Synergistic Combination

The rationale for combining ipamorelin with CJC-1295 lies in their complementary mechanisms of action. Both GHRH signalling (via CJC-1295) and ghrelin receptor signalling (via ipamorelin) stimulate GH release, but through partially independent intracellular pathways. When both pathways are activated simultaneously, the GH pulse generated is substantially greater than with either compound alone.

This synergy reflects normal physiology. Endogenous GH pulses are themselves driven by the coordinated interaction of GHRH and ghrelin — the two primary stimulatory inputs to the somatotroph cells of the anterior pituitary. Research protocols that co-administer CJC-1295 and ipamorelin are, in effect, amplifying the same dual-input mechanism that governs physiological GH secretion.

The result is a larger amplitude GH pulse, followed by downstream IGF-1 production from the liver, while maintaining the pulsatile pattern that distinguishes secretagogue-driven GH elevation from the continuous elevation produced by exogenous GH administration.

Body Composition Research

The relationship between GH, IGF-1, and body composition is well established in clinical endocrinology. GH deficiency in adults is characterised by increased visceral adiposity, reduced lean mass, impaired lipid profiles, and decreased bone mineral density. GH replacement therapy in verified GH-deficient adults consistently reverses these findings.

The question that secretagogue research investigates is whether pharmacological amplification of GH release in non-deficient individuals produces clinically meaningful body composition changes. The evidence base here is more limited than for verified deficiency states, but several lines of research are informative.

Studies in older adults, where GH secretion has declined significantly from peak levels, have shown that GH-augmenting interventions are associated with increases in lean mass and decreases in fat mass. A review by Sigalos and Pastuszak (2018) examining the safety and efficacy of GH secretagogues found that ipamorelin-class compounds were among the better-characterised agents in this literature: Sigalos & Pastuszak, 2018 — The Safety and Efficacy of Growth Hormone Secretagogues.

The anabolic effect of elevated IGF-1 on skeletal muscle — stimulating protein synthesis and satellite cell activation — provides a plausible mechanistic pathway for lean mass changes. The lipolytic effects of GH on adipose tissue, particularly visceral fat, provide the complementary pathway for fat mass reductions observed in GH-augmentation research.

Sleep Architecture and Nocturnal GH Release

Approximately 70% of physiological GH secretion occurs during slow-wave sleep (SWS), predominantly in the first half of the night. This nocturnal pulse is the largest single GH release event in the 24-hour cycle and is responsible for much of the body's protein synthesis, cellular repair, and metabolic remodelling that occurs during sleep.

Research on GH secretagogues has examined the extent to which they can amplify this nocturnal pulse. Studies using GHRH analogues have demonstrated enhanced slow-wave sleep and increased nocturnal GH secretion in older adults whose SWS and GH secretion had declined with age. This intersection of sleep architecture and GH biology represents an area of active research interest, given that both SWS disruption and GH decline are consistent features of biological ageing.

IGF-1 as a Research Biomarker

Because GH has a pulsatile secretion pattern with significant minute-to-minute variability, serum IGF-1 is typically used as the primary laboratory biomarker for GH axis activity in research settings. IGF-1 is produced primarily by the liver in response to GH stimulation, and its levels reflect integrated GH exposure over the preceding hours rather than the instantaneous GH concentration.

In research protocols using ipamorelin and CJC-1295 combinations, IGF-1 changes are commonly monitored as the primary downstream measure of secretagogue activity. The Alba et al. clinical trial documented sustained IGF-1 elevations over a multi-day period following CJC-1295 administration, providing a basis for understanding the pharmacodynamic time course.

Practical Research Considerations

Research protocols using ipamorelin and CJC-1295 share common preparation requirements with other injectable peptides. Both compounds require reconstitution with bacteriostatic water prior to use, and require cold-chain storage once reconstituted.

The standard reconstitution procedure involves adding bacteriostatic water to the lyophilised peptide vial, allowing the powder to dissolve without agitation, and storing the resulting solution refrigerated (2–8°C) with protection from light. For comprehensive reconstitution guidance including volume calculations and dilution protocols, the peptide reconstitution research guide covers these procedures in detail.

For researchers sourcing research-grade ipamorelin and CJC-1295 in Australia, RetaLABS supplies the pre-combined CJC-1295/ipamorelin formulation as a single vial, which simplifies research preparation. Individual ipamorelin and CJC-1295 vials are also available for protocols requiring independent dosing of each compound.

For an analytically-minded biohacking perspective on this compound combination, MindBodySoulDeveloper's ipamorelin and CJC-1295 research guide covers the performance optimisation context in detail.

Australian Regulatory Context

In Australia, ipamorelin and CJC-1295 are not registered therapeutic goods on the Australian Register of Therapeutic Goods (ARTG). The Therapeutic Goods Administration (TGA) classifies peptides of this type under Schedule 4 (prescription medicine) or higher scheduling, depending on the specific compound and intended use. For a full overview of how the TGA schedules research peptides and what changed with the 2025 rescheduling decisions, see the TGA peptide regulations in Australia guide.

Any use of these compounds in Australia must be conducted within the framework of applicable regulations, including the requirements of the TGA and relevant institutional ethics and research protocols. This article describes the compounds in the context of published research only.

Summary

Ipamorelin and CJC-1295 represent two of the best-characterised growth hormone secretagogues in the research literature. Their complementary mechanisms — ghrelin receptor agonism (ipamorelin) and GHRH pathway activation (CJC-1295) — produce synergistic GH pulse amplification that operates within the body's endogenous regulatory architecture. The downstream effects on IGF-1, body composition, and tissue repair pathways reflect the established physiology of the GH axis and have been the subject of substantial clinical and preclinical investigation. Another GHRH-class compound frequently studied alongside secretagogue combinations is Tesamorelin — a full-length synthetic GHRH analogue that has been specifically evaluated for visceral adipose tissue reduction. For a mechanistic breakdown of how Tesamorelin differs from CJC-1295-based protocols in targeting abdominal adiposity through the GH axis, see our dedicated article on Tesamorelin and visceral fat research.

As with all peptide research compounds, robust study of their effects in human populations remains an active and evolving area. Researchers engaging with this literature should consult primary sources and consider the limitations of extrapolating animal and small-sample human data to broader populations.